Nov 16, 2011
A matter for which Cadwalader, Wickersham & Taft LLP, one of the world’s most prominent legal advisors to financial institutions and corporations, served as counsel has been nominated for M&A Advisor’s Magnus Award for Deal of the Year. The winner will be announced at the Annual Awards Gala to be held on December 13, 2011, at the New York Athletic Club in New York City.
In the high profile deal, Cadwalader represented Pfizer Inc. in its acquisition of King Pharmaceuticals, a diversified specialty pharmaceutical discovery and clinical development company. The transaction, valued at $3.6 billion, was structured as a two-step merger, expanding Pfizer's business profile through the addition of King's three key businesses: (i) a prescription pharmaceutical business focused on delivering new formulations of pain treatments; (ii) the Meridian auto- injector business for emergency drug delivery, which develops and manufactures the EpiPen and is a long-term, critical supplier to the U.S. Department of Defense; and (iii) an animal health business that offers a variety of feed additive products.
The finalist companies chosen by M&A Advisor represent the industry’s leading firms and feature the year’s leading transactions. The winners are selected by a panel of industry judges, who review the nominations and then select the winners by individual vote. The judges are respected professionals from such fields as investment banking, private equity, management, academia, accounting, and corporate law. The criteria for selection includes perseverance, creativity and ingenuity, and the added value brought to a deal, including community benefits.
The M&A Advisor
Since 1998, The M&A Advisor has presented, recognized the achievement of and facilitated connections between the world’s leading mergers and acquisitions, financing and turnaround professionals with a comprehensive range of event and news services.
Richard Brand, Brian McGovern
Joseph Moreno, Anne Tompkins
Robert Cannon will discuss the U.K.’s new insurance-linked securities framework.